Stem cell transplantation for multiple sclerosis: what is the evidence?

Area of Science:

• Neuroimmunology
• Hematology
• Transplantation Medicine

Background:

• Multiple sclerosis (MS) is a T cell-mediated autoimmune disorder causing severe chronic disability.
• Current treatments for severe, refractory MS are often unsatisfactory, particularly for progressive or rapidly relapsing forms.
• Autologous stem cell transplantation (ASCT) offers a potential therapeutic strategy by modulating the immune system.

Purpose of the Study:

• To evaluate the feasibility and efficacy of high-dose immunosuppression followed by ASCT in patients with severe, refractory autoimmune diseases, specifically MS.
• To assess the anti-inflammatory and clinical effects of ASCT on MS disease activity and disability.
• To determine the transplant-related mortality risk associated with ASCT in MS patients.

Main Methods:

• Review of experimental and clinical observations, including phase I-II studies of ASCT in active MS patients since 1995.
• Analysis of data from 85 MS patients transplanted by the European Group for Blood and Marrow Transplantation (EBMT).
• Comparison of ASCT's impact on MRI disease parameters and clinical outcomes with conventional therapies.

Main Results:

• ASCT is a feasible treatment for active and refractory MS, demonstrating a prominent anti-inflammatory effect on MRI.
• ASCT shows a possible clinical benefit in stabilizing disease and preventing disability, with MRI impact appearing superior to conventional therapies.
• The procedure carries a transplant-related mortality risk of approximately 5% in high-risk patient groups.

Conclusions:

• ASCT may shift the immunological balance towards disease quiescence in MS.
• Clinical benefits of ASCT require validation in prospective, controlled trials to confirm superiority over standard therapies.
• A randomized trial comparing ASCT with mitoxantrone is underway to establish its role in MS treatment.